['chronic plaque type psoriasis']
['ain457 300 mg', 'ustekinumab 45/90 mg', 'placebo secukinumab']

        Inclusion Criteria:

          -  patients with moderate to severe plaque type psoriasis for at least 6 months before
             randomization

          -  patients eligible for systemic therapy with inadequately controlled psoriasis

        Exclusion Criteria:

          -  forms of sporiasis other than plaque type psoriasis

          -  previous exposure to secukinumab, ustekinumab, or other biologic drugs targeting
             (IL)-17A or IL-17RA

        Other protocol-defined inclusion/exclusion criteria may apply
      